Dr Manohara Joishy and colleagues from the United Kingdom evaluated whether fecal calprotectin and fecal lactoferrin can be used as noninvasive markers in children and young people with active inflammatory bowel disease (IBD).
Stool samples were collected from 3 groups of children: those with active IBD, control individuals with other gastrointestinal diseases (GI control) and control individuals with no gastrointestinal disease (non-GI control).
The number of patients for the fecal calprotectin assay was as follows: IBD = 26, GI controls = 30, non-GI control = 25.
|Median concentrations of fecal calprotectin were higher in the IBD group|
|Journal of Pediatric Gastroenterology & Nutrition|
The number of patients for the fecal lactoferrin assay was as follows: IBD = 24, GI control = 26, non-GI controls = 24.
The research team reported that fecal calprotectin and fecal lactoferrin were measured by use of enzyme-linked immunoassays.
The researchers noted that the median concentrations of fecal calprotectin and fecal lactoferrin in isolation, and their interaction, were higher in the IBD group than in the GI and non-GI control groups.
Although the area under the curve, sensitivity, and specificity for fecal calprotectin, fecal lactoferrin and their interaction were significantly better than chance.
The team observed that fecal lactoferrin consistently had the lowest area under the curve, and their interaction consistently had the highest area under the curve.
Dr Joishy’s team concludes, “Fecal calprotectin and fecal lactoferrin are both significantly elevated in children with IBD, and the interaction of these 2 biomarkers may produce a better initial diagnostic test compared with their use in isolation.”